In 2016, more than 1.9 billion adults of 18 years old were overweight, of this, 650 million were obese, indicating that 39% of adults of the world's population aged 18 were overweight (39% of men and 40% of women) and 13% were obese (11% of men and 15% of women) (131)
Furthermore, the risk of hyperkalemia has been shown to be elevated with spironolactone, [62, 64] and this also limits its use for combination with RAAS inhibitors
Clinical trials indicate Mounjaro users experience greater weight loss than those on Wegovy, along with additional health benefits, but accessibility and high costs pose challenges for potential users
to ensure they are safe and effective for specific uses
Numerous other agents (oral semaglutide Rybelsus , injectable dulaglutide Trulicity for diabetes only, Eli Lillys oral non-peptide orforglipron submitted to FDA, etc.) fall under this family